Safinamide
MAO-B Inhibitor
Product Specifications
Background
A selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A) (1). It displays anticonvulsant activity (2) and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models (3). Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade (4). A novel therapeutic for Parkinson’s disease with multiple modes of action (5). Effective as an add-on to dopamine agonist therapy in early Parkinson’s Disease(6).
CAS Number
133865-89-1
Product Name Alternative
(S) - (+) -2-[[4- (3-Fluorobenzoxy) benzyl]amino]propanamide; FCE-26743; PNU-151774E; NW-1015
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Neuroscience | Neurodegeneration | Parkinson's Disease
Purity
>98% (HPLC) ; NMR (Conforms)
Weight
0.005
Format
White powder
Solubility
May be dissolved in DMSO (50 mg/ml)
Molecular Formula
C17H19FN2O2
Molecular Weight
302.3
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. MS Strolin Benedetti et al. 1994 J. Pharm. Pharmacol. 46:814
2. RG Fariello et al. 1998 J. Pharmacol. Exp. Ther. 285:397
3. R Maj et al.1998 Eur. J. Pharmacol. 8 359:27
4. F Gardoni et al. 2018 J. Pharmacol. Exp. Ther. 2018 367:442
5. C Caccia et al. 2006 Neurology 67(7 Suppl. 2):S18
6. AH Schapira et al. 2013 Eur. J. Neurol. 20:271
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
